Literature DB >> 31389699

Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands.

Ziqian Wang, Nianzhe He, Zongwei Guo, Cuili Niu, Ting Song, Yafei Guo, Keke Cao, Anhui Wang, Junjie Zhu, Xiaodong Zhang, Zhichao Zhang.   

Abstract

Proteolysis targeting chimera (PROTAC) recruits an E3 ligase to a target protein to induce its ubiquitination and subsequent degradation. We reported success in the development of two PROTACs (C3 and C5) that potently and selectively induce the degradation of Mcl-1 and Bcl-2 (DC50 = 0.7 and 3.0 μM), respectively, by introducing the E3 ligase cereblon-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitors S1-6 and Nap-1 with micromolar-range affinity. C3-induced Mcl-1 ubiquitination translated into much more lethality in Mcl-1-dependent H23 cells than the most potent Mcl-1 occupancy-based inhibitor A-1210477 with nanomolar-range affinity. Moreover, structure-activity relationship analysis and molecular dynamic simulations discovered the structural basis for turning nonselective or promiscuous Bcl-2 family ligands into selective PROTACs. C3 and C5 exhibited reversible depletion in living cells, which provides a new potent toolkit for gain-of-function studies to probe the dynamic roles of Bcl-2 and Mcl-1 in apoptosis networks.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31389699     DOI: 10.1021/acs.jmedchem.9b00919

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

2.  Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality.

Authors:  Philip P Chamberlain; Laura A D'Agostino; J Michael Ellis; Joshua D Hansen; Mary E Matyskiela; Joseph J McDonald; Jennifer R Riggs; Lawrence G Hamann
Journal:  ACS Med Chem Lett       Date:  2019-11-12       Impact factor: 4.345

3.  Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.

Authors:  Maha Hanafi; Xinde Chen; Nouri Neamati
Journal:  J Med Chem       Date:  2021-01-28       Impact factor: 7.446

Review 4.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

5.  Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.

Authors:  Xuan Zhang; Dinesh Thummuri; Xingui Liu; Wanyi Hu; Peiyi Zhang; Sajid Khan; Yaxia Yuan; Daohong Zhou; Guangrong Zheng
Journal:  Eur J Med Chem       Date:  2020-02-27       Impact factor: 6.514

Review 6.  Targeted protein degradation: A promise for undruggable proteins.

Authors:  Kusal T G Samarasinghe; Craig M Crews
Journal:  Cell Chem Biol       Date:  2021-05-17       Impact factor: 9.039

Review 7.  PROTACs: An Emerging Therapeutic Modality in Precision Medicine.

Authors:  Dhanusha A Nalawansha; Craig M Crews
Journal:  Cell Chem Biol       Date:  2020-08-13       Impact factor: 9.039

Review 8.  Assays and technologies for developing proteolysis targeting chimera degraders.

Authors:  Xingui Liu; Xuan Zhang; Dongwen Lv; Yaxia Yuan; Guangrong Zheng; Daohong Zhou
Journal:  Future Med Chem       Date:  2020-05-20       Impact factor: 3.808

Review 9.  Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.

Authors:  Yonghan He; Sajid Khan; Zhiguang Huo; Dongwen Lv; Xuan Zhang; Xingui Liu; Yaxia Yuan; Robert Hromas; Mingjiang Xu; Guangrong Zheng; Daohong Zhou
Journal:  J Hematol Oncol       Date:  2020-07-27       Impact factor: 17.388

10.  PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors.

Authors:  Peiyi Zhang; Xuan Zhang; Xingui Liu; Sajid Khan; Daohong Zhou; Guangrong Zheng
Journal:  Explor Target Antitumor Ther       Date:  2020-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.